Screening for insulinoma antigen 2 and zinc transporter 8 autoantibodies: a cost-effective and age-independent strategy to identify rapid progressors to clinical onset among relatives of type 1 diabetic patients

Contribution of Antibodies Against IA-2β and Zinc Transporter 8 to Classification of Diabetes Diagnosed Under 40 Years of Age

(2011) Ilse Vermeulen et al.   DIABETES CARE

Age of Islet Autoantibody Appearance and Mean Levels of Insulin, but Not GAD or IA-2 Autoantibodies, Predict Age of Diagnosis of Type 1 Diabetes: Diabetes Autoimmunity Study in the Young

(2011) A. K. Steck et al.   DIABETES CARE

An important minority of prediabetic first-degree relatives of type 1 diabetic patients derives from seroconversion to persistent autoantibody positivity after 10 years of age

(2011) I. Vermeulen et al.   DIABETOLOGIA

The Role of Autoantibodies to Zinc Transporter 8 in Prediction of Type 1 Diabetes in Relatives: Lessons from the European Nicotinamide Diabetes Intervention Trial (ENDIT) Cohort

(2011) Anna E. Long et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Anti-CD3 antibodies for type 1 diabetes: beyond expectations

(2011) Jean-François Bach   LANCET

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial

(2011) Nicole Sherry et al.   LANCET

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial

(2011) Tihamer Orban et al.   LANCET

Type 1 diabetes mellitus—a door opening to a real therapy?

(2011) Lucienne Chatenoud   Nature Reviews Endocrinology

Sample Size Requirements for Studies of Treatment Effects on Beta-Cell Function in Newly Diagnosed Type 1 Diabetes

(2011) John M. Lachin et al.   PLoS One

Predicting Adult-Onset Autoimmune Diabetes: Clarity From Complexity

(2010) R. D. Leslie   DIABETES

Stopping Type 1 Diabetes: Attempts to Prevent or Cure Type 1 Diabetes in Man

(2010) J. S. Skyler et al.   DIABETES

Enhancing the Understanding of Pre-Type 1 Diabetes in the General Population

(2010) O. Simell et al.   DIABETES CARE

Prediction of Type 1 Diabetes in the General Population

(2010) M. Knip et al.   DIABETES CARE

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass

(2010) B. Keymeulen et al.   DIABETOLOGIA

Novel antigens in type 1 diabetes: The importance of ZnT8

(2009) Janet M. Wenzlau et al.   Current Diabetes Reports

Immunotherapy for the Prevention and Treatment of Type 1 Diabetes: Human trials and a look into the future

(2009) M. Rewers et al.   DIABETES CARE

Trends of Earlier and Later Responses of C-peptide to Oral Glucose Challenges With Progression to Type 1 Diabetes in Diabetes Prevention Trial-Type 1 Participants

(2009) J. M. Sosenko et al.   DIABETES CARE

Pancreatic Islet Autoantibodies as Predictors of Type 1 Diabetes in the Diabetes Prevention Trial-Type 1

(2009) T. Orban et al.   DIABETES CARE

Predictive power of screening for antibodies against insulinoma-associated protein 2 beta (IA-2β) and zinc transporter-8 to select first-degree relatives of type 1 diabetic patients with risk of rapid progression to clinical onset of the disease: implications for prevention trials

(2009) J. De Grijse et al.   DIABETOLOGIA

Hyperglycaemic clamp test for diabetes risk assessment in IA-2-antibody-positive relatives of type 1 diabetic patients

(2009) E. Vandemeulebroucke et al.   DIABETOLOGIA

Triple chimeric islet autoantigen IA2–ZnT8WR to facilitate islet autoantibody determination

(2009) Liping Yu et al.   JOURNAL OF IMMUNOLOGICAL METHODS

Maternal type 1 diabetes reduces the risk of islet autoantibodies: relationships with birthweight and maternal HbA1c

(2008) E. Bonifacio et al.   DIABETOLOGIA